E-THERAPEUTICS

Serial Number 97497975
Registration 7567980
700

Registration Progress

Application Filed
Jul 11, 2022
Under Examination
Apr 16, 2024
Approved for Publication
Jan 31, 2024
Published for Opposition
Feb 20, 2024
Registered
Nov 19, 2024

Trademark Image

E-THERAPEUTICS

Basic Information

Serial Number
97497975
Registration Number
7567980
Filing Date
July 11, 2022
Registration Date
November 19, 2024
Published for Opposition
February 20, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 19, 2024
Registration
Registered
Classes
005 009 040 042

Rights Holder

E-THERAPEUTICS PLC

99
Address
4 Kingdom Street
London W26BD
GB

Ownership History

E-THERAPEUTICS PLC

Original Applicant
99
London GB

E-THERAPEUTICS PLC

Owner at Publication
99
London GB

E-THERAPEUTICS PLC

Original Registrant
99
London GB

Legal Representation

Attorney
Anna King

USPTO Deadlines

Next Deadline
1837 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-19)
Due Date
November 19, 2030
Grace Period Ends
May 19, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

30 events
Date Code Type Description Documents
Nov 19, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Nov 19, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Oct 15, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Oct 15, 2024 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Oct 15, 2024 DP1B I 1(B) BASIS DELETED; PROCEED TO REGISTRATION Loading...
Sep 26, 2024 D1BR I TEAS DELETE 1(B) BASIS RECEIVED Loading...
Sep 12, 2024 EPPA I TEAS POST PUBLICATION AMENDMENT RECEIVED Loading...
Apr 16, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 4, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 20, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 31, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 31, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 18, 2024 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Jan 12, 2024 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Jan 7, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 5, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 5, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 5, 2024 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jan 5, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 30, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 30, 2023 ALIE A ASSIGNED TO LIE Loading...
Nov 30, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 26, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 27, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 27, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 27, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 25, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 19, 2023 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Jul 29, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 14, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; none of the aforementioned goods for, or related to, T-cells or T-cell receptors
Class 009
Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; downloadable databases in the field of pharmaceuticals, medicines and drug discovery; electronic databases recorded on computer media, for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; none of the aforementioned goods for, or related to, T-cells or T-cell receptors
Class 040
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid; none of the aforementioned services for, or related to, T-cells or T-cell receptors
Class 042
Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software; design, development, creation and maintenance of computational computer software platforms; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS); Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid; none of the aforementioned services for, or related to, T-cells or T-cell receptors

Classification

International Classes
005 009 040 042